Automated Method Development for High Throughput Purification at Nurix Therapeutics

By AldenMC Production / May 28, 2024

Post navigation

Latest Results from an Ongoing First-in-Human Phase 1a/b Study of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory CLL and Other B-cell Malignancies

WHERE SCIENCE EXPANDS POSSIBILITIES

Inside The Science

DEL-AI Discovery Engine
Targeted Protein Degradation
Resource Library

Advancing Our Pipeline

Pipeline
Clinical Trials

Learn About Us

Our Story
Leadership
Partnering
Contact Us

Work at Nurix

Our Culture
Explore Jobs

For Investors

News & Events
Financial Information
Stock Information
Corporate Governance
FAQs
Investor Contact

For Patients

Resources

You are now leaving the nurixtx.com website. This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Cancel

Continue